MicroRNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray

Malaysian Journal of Pathology

Volumn 34, Issue 2, 2012, Pages 133-143

  Yusnita, Yusnita ^a   Norsiah, M D ^a   Zakiah, I ^a   Chang, K M ^b   Purushotaman, V S ^b   Zubaidah, Z ^a   Jamal, R ^c  

^a INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^b Ampang Hospital   (Malaysia)

^c UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Biomarker; MicroRNA; MiRNA expression; Multiple myeloma

Indexed keywords

CYCLIN D2; HIGH MOBILITY GROUP A2 PROTEIN; LET 7C PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 16; MICRORNA 181A; MICRORNA 181B; MICRORNA 449; SOMATOMEDIN C RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BONE MARROW BIOPSY; CCND2 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; HMG2 GENE; HUMAN; HUMAN TISSUE; IGF1R GENE; MALE; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; PREDICTION; RNA ANALYSIS; UPREGULATION;

ADULT; AGED; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MULTIPLE MYELOMA; TISSUE ARRAY ANALYSIS; UP-REGULATION;

EID: 84872142342     PISSN: 01268635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78(1): 21-33.
2. Pratt G. Molecular aspects of multiple myeloma. Mol Pathol. 2002; 55(5): 273-83.
3. Durie BGM. Patient handbook: multiple myeloma, cancer of the bone marrow. 2010/2011 ed. California: International Myeloma Foundation; 2010.
4. Norsiah MD, Aishah AWS, Nizam MKMK, Zamtira S. Trends of monoclonal gammopathies in Malaysia. 2011 (Unpublished report).
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281-97.
6. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19(1): 92-105.
7. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006; 11(4): 441-50.
8. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med. 2006; 12(12): 580-7.
9. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99(24): 15524-9.
10. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64(11): 3753-6.
11. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008; 105(35): 12885-90.
12. Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009; 113(26): 6669-80.
13. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia. 2010; 24(3): 629-37.
14. Pilarski LM, Mant MJ, Ruether BA. Pre-B cells in peripheral blood of multiple myeloma patients. Blood. 1985; 66(2): 416-22.
15. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1987; 23(6): 707-12.
16. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003; 101(4): 1520-9.
17. Collado M, Garcia V, Garcia JM, et al. Genomic profiling of circulating plasma RNA for the analysis of cancer. Clin Chem. 2007; 53(10): 1860-3.
18. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30): 10513-8.
19. Lu M, Zhang Q, Deng M, et al. An analysis of human microRNA and disease associations. PLoS One. 2008; 3(10): e3420.
20. Avet-Loiseau H, Mangrangeas F., Moreau P., Attal M., Facon T., Anderson K. et al. 2011. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol DOI: 10. 1200/JCO.2010.32.8435
21. Feezor RJ, Baker HV, Mindrinos M, et al. Whole blood and leucocytes RNA isolation for gene expression analyses. Physiol Genomics 2004; 19: 247-54.
22. Debey S, Schoenbeck U, Hellmich M, et al. Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses on overall expression and the role of different cell types. Pharmacogenomics J 2004; 4: 193-207.
23. Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. RNA 2007; 13: 151-9.
24. Repsilber D, Kern S, Telaar A, et al. Biomarker discovery in heterogeneous tissue samples-taking the in-silico deconfounding approach. BMC Bioinformatics. 2010; 11: 27.
25. Chin LJ, Slack FJ. A truth serum for cancermicroRNAs have major potential as cancer biomarkers. Cell Res. 2008; 18(10): 983-4.
26. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J, Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005; 106(1): 296-303.
27. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39): 13944-9.
28. Linsley PS, Schelter J, Burchard J, et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol. 2007; 27(6): 2240-52.
29. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005; 33(17): 5394-403.